Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Codiak BioSciences news
27.03.2023
Codiak BioSciences has filed for protection under Chapter 11 of the U.S. Bankruptcy Code. Company expects to complete the sale of the entire business or its principal assets as soon as possible.
Source: 
ir.codiakbio.com
ir.codiakbio.com
06.05.2022
Codiak BioSciences' GAAP loss for 3 months of 2022 was $8.028 million, down 22.1% from $10.308 million in the previous year. Revenue decreased 3.7% to $12.704 million from $13.191 million a year earlier.
Source: ir.codiakbio.com
ir.codiakbio.com
11.03.2022
Codiak BioSciences' GAAP loss for 2021 was $37.157 million, down 59.5% from $91.665 million in the previous year. Revenue increased 7.87 times to $22.935 million from $2.915 million a year earlier.
Source: ir.codiakbio.com
ir.codiakbio.com
05.11.2021
Codiak BioSciences' GAAP loss for 9M 2021 was $53.819 million, down 27% from $73.708 million in the previous year. Revenue increased 12-fold to $15.238 million from $1.275 million a year earlier.
Source: ir.codiakbio.com
ir.codiakbio.com
General information
| Company name | Codiak BioSciences |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 35 CambridgePark Drive Suite 500 Cambridge, MA 02139 United States |
| Website | www.codiakbio.com |
| Information disclosure | www.sec.gov |
English (US) 